BMS-963272 + Placebo
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Obese But Otherwise Healthy Participants
Conditions
Obese But Otherwise Healthy Participants
Trial Timeline
Sep 30, 2019 → Feb 10, 2020
NCT ID
NCT04116632About BMS-963272 + Placebo
BMS-963272 + Placebo is a phase 1 stage product being developed by Bristol Myers Squibb for Obese But Otherwise Healthy Participants. The current trial status is completed. This product is registered under clinical trial identifier NCT04116632. Target conditions include Obese But Otherwise Healthy Participants.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04116632 | Phase 1 | Completed |
| NCT02327273 | Phase 1 | Completed |
Competing Products
9 competing products in Obese But Otherwise Healthy Participants
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lorcaserin | Eisai | Phase 1 | 33 |
| Bardoxolone methyl + Placebo | Kyowa Kirin | Phase 1 | 33 |
| LIK066 + Placebo | Novartis | Phase 2 | 52 |
| Investigational new drug company code: BGS649 + Placebo | Novartis | Phase 2 | 52 |
| Placebo + CT-388 | Roche | Phase 2 | 52 |
| Growth hormone treatment | Pfizer | Pre-clinical | 22 |
| ALN-4324 + Placebo | Alnylam Pharmaceuticals | Phase 1/2 | 38 |
| Aleniglipron + Placebo | Structure Therapeutics | Phase 2 | 47 |
| CRB-913 + Placebo | Corbus Pharmaceuticals | Phase 1 | 25 |